KR20190026962A - 세균질증 치료에 사용하기 위한 세크니다졸 - Google Patents
세균질증 치료에 사용하기 위한 세크니다졸 Download PDFInfo
- Publication number
- KR20190026962A KR20190026962A KR1020197006430A KR20197006430A KR20190026962A KR 20190026962 A KR20190026962 A KR 20190026962A KR 1020197006430 A KR1020197006430 A KR 1020197006430A KR 20197006430 A KR20197006430 A KR 20197006430A KR 20190026962 A KR20190026962 A KR 20190026962A
- Authority
- KR
- South Korea
- Prior art keywords
- subject
- administration
- formulation
- treatment
- bacterial vaginosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000004926 Bacterial Vaginosis Diseases 0.000 title claims abstract description 333
- 208000037009 Vaginitis bacterial Diseases 0.000 title claims abstract description 311
- 238000011282 treatment Methods 0.000 title claims abstract description 286
- KPQZUUQMTUIKBP-UHFFFAOYSA-N 1-(2-methyl-5-nitro-1-imidazolyl)-2-propanol Chemical compound CC(O)CN1C(C)=NC=C1[N+]([O-])=O KPQZUUQMTUIKBP-UHFFFAOYSA-N 0.000 title description 53
- 229960004076 secnidazole Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 203
- 238000009472 formulation Methods 0.000 claims abstract description 202
- 238000000034 method Methods 0.000 claims abstract description 199
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims abstract description 68
- 229960002073 sertraline Drugs 0.000 claims abstract description 68
- 208000024891 symptom Diseases 0.000 claims description 218
- 210000003756 cervix mucus Anatomy 0.000 claims description 94
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 79
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 79
- 230000001580 bacterial effect Effects 0.000 claims description 79
- 229960002568 ethinylestradiol Drugs 0.000 claims description 79
- 206010046901 vaginal discharge Diseases 0.000 claims description 75
- 238000012360 testing method Methods 0.000 claims description 72
- 239000000463 material Substances 0.000 claims description 71
- 241001676635 Lepidorhombus whiffiagonis Species 0.000 claims description 63
- 235000013305 food Nutrition 0.000 claims description 58
- 239000004531 microgranule Substances 0.000 claims description 48
- 239000008187 granular material Substances 0.000 claims description 45
- 210000004027 cell Anatomy 0.000 claims description 44
- 210000002919 epithelial cell Anatomy 0.000 claims description 43
- 230000002159 abnormal effect Effects 0.000 claims description 38
- 229940124602 FDA-approved drug Drugs 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 31
- 206010046935 Vaginal odour Diseases 0.000 claims description 27
- 241000287436 Turdus merula Species 0.000 claims description 23
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 claims description 18
- 239000002245 particle Substances 0.000 claims description 16
- 229940053934 norethindrone Drugs 0.000 claims description 15
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 15
- 229920003163 Eudragit® NE 30 D Polymers 0.000 claims description 12
- 230000001747 exhibiting effect Effects 0.000 claims description 12
- 239000000454 talc Substances 0.000 claims description 12
- 229910052623 talc Inorganic materials 0.000 claims description 12
- 208000036142 Viral infection Diseases 0.000 claims description 11
- 238000004458 analytical method Methods 0.000 claims description 11
- 230000003111 delayed effect Effects 0.000 claims description 11
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 11
- 230000009385 viral infection Effects 0.000 claims description 11
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims description 10
- 229960000652 sertindole Drugs 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 8
- 239000003433 contraceptive agent Substances 0.000 claims description 8
- 230000002254 contraceptive effect Effects 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 229940069328 povidone Drugs 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 7
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 6
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 5
- 229940081974 saccharin Drugs 0.000 claims description 5
- 235000019204 saccharin Nutrition 0.000 claims description 5
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 5
- 206010047700 Vomiting Diseases 0.000 claims description 3
- 230000008673 vomiting Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims 2
- 241001670157 Gymnura Species 0.000 claims 1
- 239000003094 microcapsule Substances 0.000 claims 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 86
- 206010044620 Trichomoniasis Diseases 0.000 description 84
- 206010046914 Vaginal infection Diseases 0.000 description 43
- 241000725303 Human immunodeficiency virus Species 0.000 description 30
- 229920002684 Sepharose Polymers 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
- 239000011780 sodium chloride Substances 0.000 description 23
- 235000015067 sauces Nutrition 0.000 description 22
- 208000015181 infectious disease Diseases 0.000 description 21
- 235000011962 puddings Nutrition 0.000 description 21
- 235000013618 yogurt Nutrition 0.000 description 21
- 206010013990 dysuria Diseases 0.000 description 20
- 230000001568 sexual effect Effects 0.000 description 19
- 235000021058 soft food Nutrition 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- 206010047486 Virilism Diseases 0.000 description 18
- 239000002552 dosage form Substances 0.000 description 17
- 208000004483 Dyspareunia Diseases 0.000 description 15
- 201000008100 Vaginitis Diseases 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 230000000306 recurrent effect Effects 0.000 description 15
- 239000003550 marker Substances 0.000 description 14
- 208000005107 Premature Birth Diseases 0.000 description 13
- 206010036590 Premature baby Diseases 0.000 description 13
- 230000035876 healing Effects 0.000 description 12
- 230000036470 plasma concentration Effects 0.000 description 12
- 238000011121 vaginal smear Methods 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 238000010348 incorporation Methods 0.000 description 11
- 206010000084 Abdominal pain lower Diseases 0.000 description 10
- 208000032843 Hemorrhage Diseases 0.000 description 10
- 208000003251 Pruritus Diseases 0.000 description 10
- 208000034158 bleeding Diseases 0.000 description 10
- 230000000740 bleeding effect Effects 0.000 description 10
- 230000000580 secretagogue effect Effects 0.000 description 10
- 208000035143 Bacterial infection Diseases 0.000 description 9
- 208000022362 bacterial infectious disease Diseases 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 208000000143 urethritis Diseases 0.000 description 9
- 208000004746 Atrophic Vaginitis Diseases 0.000 description 8
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 8
- 206010036018 Pollakiuria Diseases 0.000 description 8
- 201000003146 cystitis Diseases 0.000 description 8
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 8
- 235000021055 solid food Nutrition 0.000 description 8
- 208000022934 urinary frequency Diseases 0.000 description 8
- 230000036318 urination frequency Effects 0.000 description 8
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 238000011260 co-administration Methods 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 239000002853 nucleic acid probe Substances 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000376 reactant Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 238000009533 lab test Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000009007 Diagnostic Kit Methods 0.000 description 5
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 239000003518 caustics Substances 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 201000006549 dyspepsia Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 210000000224 granular leucocyte Anatomy 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 238000000386 microscopy Methods 0.000 description 5
- 238000011321 prophylaxis Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 241000224526 Trichomonas Species 0.000 description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 230000002025 microglial effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- VYDWQPKRHOGLPA-UHFFFAOYSA-N 5-nitroimidazole Chemical compound [O-][N+](=O)C1=CN=CN1 VYDWQPKRHOGLPA-UHFFFAOYSA-N 0.000 description 3
- 241000606153 Chlamydia trachomatis Species 0.000 description 3
- 206010046788 Uterine haemorrhage Diseases 0.000 description 3
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 230000004899 motility Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 241000224527 Trichomonas vaginalis Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000010030 laminating Methods 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000003905 vulva Anatomy 0.000 description 2
- -1 5-nitroimidazole compound Chemical class 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 208000035010 Term birth Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940110839 nuvessa Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
- C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046731P | 2014-09-05 | 2014-09-05 | |
| US62/046,731 | 2014-09-05 | ||
| US201562101636P | 2015-01-09 | 2015-01-09 | |
| US62/101,636 | 2015-01-09 | ||
| PCT/US2015/048681 WO2016037131A1 (en) | 2014-09-05 | 2015-09-04 | Secnidazole for use in the treatment of bacterial vaginosis |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177009154A Division KR20170052626A (ko) | 2014-09-05 | 2015-09-04 | 세균질증 치료에 사용하기 위한 세크니다졸 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20190026962A true KR20190026962A (ko) | 2019-03-13 |
Family
ID=55436475
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177009154A Ceased KR20170052626A (ko) | 2014-09-05 | 2015-09-04 | 세균질증 치료에 사용하기 위한 세크니다졸 |
| KR1020197006430A Ceased KR20190026962A (ko) | 2014-09-05 | 2015-09-04 | 세균질증 치료에 사용하기 위한 세크니다졸 |
| KR1020190088946A Withdrawn KR20200013602A (ko) | 2014-09-05 | 2019-07-23 | 세균성 질증의 치료에 사용하기 위한 세크니다졸 |
| KR1020200079140A Withdrawn KR20200083958A (ko) | 2014-09-05 | 2020-06-29 | 세균성 질증의 치료에 사용하기 위한 세크니다졸 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177009154A Ceased KR20170052626A (ko) | 2014-09-05 | 2015-09-04 | 세균질증 치료에 사용하기 위한 세크니다졸 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190088946A Withdrawn KR20200013602A (ko) | 2014-09-05 | 2019-07-23 | 세균성 질증의 치료에 사용하기 위한 세크니다졸 |
| KR1020200079140A Withdrawn KR20200083958A (ko) | 2014-09-05 | 2020-06-29 | 세균성 질증의 치료에 사용하기 위한 세크니다졸 |
Country Status (6)
| Country | Link |
|---|---|
| US (10) | US10335390B2 (enExample) |
| JP (4) | JP6487534B2 (enExample) |
| KR (4) | KR20170052626A (enExample) |
| AU (3) | AU2015311674B2 (enExample) |
| CA (2) | CA2959414C (enExample) |
| WO (1) | WO2016037131A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201319791D0 (en) * | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| WO2016037131A1 (en) * | 2014-09-05 | 2016-03-10 | Symbiomix Therapeutics, Llc | Secnidazole for use in the treatment of bacterial vaginosis |
| CA2988082C (en) | 2015-06-01 | 2020-09-29 | Symbiomix Therapeutics, Llc | Novel nitroimidazole formulations and uses thereof |
| US20190008784A1 (en) * | 2017-07-07 | 2019-01-10 | Symbiomix Therapeutics, Llc | Novel secnidazole soft gelatin capsule formulations and uses thereof |
| KR20210065958A (ko) | 2018-09-05 | 2021-06-04 | 루핀 인코포레이티드 | 세균성 질증의 치료에 사용하기 위한 중수소화된 세크니다졸 및 이의 방법 및 용도 |
| KR200496054Y1 (ko) | 2020-06-01 | 2022-10-21 | 엄경미 | 사이즈 조절기능을 갖는 드레스 |
| US12280037B2 (en) | 2020-09-22 | 2025-04-22 | Evofem Biosciences, Inc. | Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof |
| CA3193245A1 (en) * | 2020-09-22 | 2022-03-31 | Helen S. PENTIKIS | Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA922319A (en) | 1964-10-26 | 1973-03-06 | Pfizer Limited | Process of preparing 5-nitroimidazole derivatives |
| JPS6037735B2 (ja) | 1978-10-18 | 1985-08-28 | 住友電気工業株式会社 | 人工血管 |
| IN156886B (enExample) | 1981-08-22 | 1985-11-30 | Council Scient Ind Res | |
| NZ210785A (en) | 1984-01-13 | 1987-11-27 | Battelle Development Corp | Liquid dispersions of layered controlled release dosage forms |
| EP0707854B1 (en) | 1985-06-13 | 2006-02-22 | Barry James Dr. Marshall | Compositions for the treatment of gastronitestinal disorders containing bismuth and an antimicrobial |
| US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
| GB8607159D0 (en) | 1986-03-22 | 1986-04-30 | Smith & Nephew Ass | Pharmaceutical composition |
| JPH01500034A (ja) | 1986-04-10 | 1989-01-12 | ダラテック プロプライエタリー リミテッド | ワクチンおよび植込剤 |
| US5140055A (en) | 1986-07-01 | 1992-08-18 | Bridgestone Corporation | Rubber composition |
| US4920141A (en) | 1986-10-06 | 1990-04-24 | Petrolite Corporation | Synergistic biocides of certain nitroimidazoles and aldehydes |
| US5026694A (en) | 1987-04-13 | 1991-06-25 | The British Columbia Cancer Foundation | Platinum complexes with one radiosensitizing ligand |
| US4816339A (en) | 1987-04-28 | 1989-03-28 | Baxter International Inc. | Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation |
| FR2625999B1 (fr) | 1988-01-15 | 1990-06-08 | Rhone Poulenc Sante | Procede de preparation d'hydroxyalkyl-1 methyl-2 nitro-5 imidazoles |
| FR2625998B1 (fr) | 1988-01-15 | 1990-06-08 | Rhone Poulenc Sante | Procede de preparation d'hydroxyalkyl-1 methyl-2 nitro-5 imidazoles |
| FR2625996B1 (fr) | 1988-01-15 | 1990-06-08 | Rhone Poulenc Sante | Procede de preparation d'agents d'hydroxyalkylation, les nouveaux agents ainsi obtenus et leur emploi |
| US4957918A (en) | 1988-06-09 | 1990-09-18 | Leonard Bloom | Topical treatment of blepharitis |
| US5614545A (en) | 1988-06-09 | 1997-03-25 | Leonard Bloom | Topical composition for treatment of blepharitis |
| DE3822095A1 (de) | 1988-06-30 | 1990-01-04 | Klinge Co Chem Pharm Fab | Neue arzneimittelformulierung sowie verfahren zu deren herstellung |
| DE3900811A1 (de) | 1989-01-13 | 1990-07-19 | Kali Chemie Pharma Gmbh | Neue arzneiform |
| IT1230047B (it) | 1989-07-04 | 1991-09-27 | Giovanni Brotzu | Protesi vascolare contenente nella parete microcapsule inglobanti cellule produttrici di ormoni. |
| IE902829A1 (en) | 1989-08-14 | 1991-02-27 | Eurand America | Microencapsulated taste-masked water-insoluble nsaid drug¹materials |
| DE3930669A1 (de) | 1989-09-14 | 1991-03-28 | Basf Ag | Verfahren zur herstellung von uretdiongruppen aufweisenden polyisocyanaten |
| CA2082398C (en) | 1990-05-14 | 2004-06-29 | Gary R. Jernberg | Surgical implant and method incorporating chemotherapeutic agents |
| IT1253711B (it) | 1991-12-17 | 1995-08-23 | Alfa Wassermann Spa | Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali |
| IL104093A (en) | 1991-12-31 | 1999-06-20 | Abbott Lab | Prolamine is expected to mask the taste of drugs given orally |
| IT1255895B (it) | 1992-10-20 | 1995-11-17 | Laura Chiodini | Composizioni farmaceutiche contenenti una calcitonina |
| IT1264020B (it) * | 1993-01-28 | 1996-09-09 | Recordati Chem Pharm | Procedimento per la preparazione di microgranuli idonei alla sospensione in liquidi |
| ZA9410186B (en) | 1994-01-10 | 1995-08-25 | Santiago Abelardo Bojali Jaber | Savourless antiamoebic antiprotozoan chemical product and procedure to obtain it |
| RU2152212C1 (ru) * | 1994-01-14 | 2000-07-10 | Лаборатуар Де Продюи Этик Этифарм | Лекарственная форма производных 5-нитроимидазола |
| US5549911A (en) | 1994-01-14 | 1996-08-27 | Laboratoires Des Produits Ethiques Ethypharm | Galenic form of 5-nitromidazole derivatives which is effective for the treatment of parasitoses and infections of the entire gastrointestinal tract |
| US6103262A (en) | 1994-01-27 | 2000-08-15 | G. D. Searle & Company | Modified-release metronidazole compositions and methods for making and using same |
| EP0717992A3 (en) | 1994-12-21 | 1998-03-25 | McNEIL-PPC, INC. | Aqueous suspension formulations for pharmaceutical applications |
| PE48297A1 (es) | 1995-05-09 | 1998-02-04 | Procter & Gamble | Metodos y composiciones para la prevencion y el tratamiento de desordenes gastrointestinales |
| US6214386B1 (en) * | 1995-11-22 | 2001-04-10 | Recordati, S.A. | Prompt-release oral pharmaceutical compositions for extemporaneous suspensions |
| FR2759293B1 (fr) * | 1997-02-11 | 1999-04-30 | Ethypharm Lab Prod Ethiques | Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie |
| US5904937A (en) | 1997-10-03 | 1999-05-18 | Fmc Corporation | Taste masked pharmaceutical compositions |
| US7884090B2 (en) | 1999-03-17 | 2011-02-08 | Ernest L. Bonner, Jr. | Compositions and methods for the treatment of arthritis |
| US7691831B2 (en) | 1999-03-17 | 2010-04-06 | Ernest L. Bonner, Jr. | Pharmaceutical combination and method for treatment of reactive arthritis or bursitis |
| FR2791888B1 (fr) | 1999-04-06 | 2004-10-08 | Ethypharm Lab Prod Ethiques | Suspension pharmaceutique buvable |
| ES2234581T3 (es) | 1999-04-06 | 2005-07-01 | Ethypharm | Suspension farmaceutica bebible de ibuprofeno. |
| KR100671879B1 (ko) | 1999-07-16 | 2007-01-19 | 가부시키가이샤 쇼에이 | 니트로이미다졸 함유 피부 질환용 외용제 |
| IT1317735B1 (it) | 2000-01-26 | 2003-07-15 | Nicox Sa | Sali di agenti antimicrobici. |
| RU2266114C2 (ru) | 2000-01-31 | 2005-12-20 | Исихара Сангио Кайся, Лтд. | Средство для лечения и профилактики заболеваний системы органов пищеварения, содержащее производное диаминотрифторметилпиридина |
| US7234062B2 (en) | 2000-07-18 | 2007-06-19 | General Electric Company | Authentication of remote appliance messages using an embedded cryptographic device |
| CA2463624A1 (en) | 2001-10-15 | 2003-04-24 | National Research Council Of Canada | Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications |
| US20030091540A1 (en) | 2001-10-16 | 2003-05-15 | Nawaz Ahmad | Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity |
| US20050261298A1 (en) | 2002-01-18 | 2005-11-24 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
| US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
| KR20050025166A (ko) | 2002-05-01 | 2005-03-11 | 맥네일-피피씨, 인코포레이티드 | 가온성 및 무자극성 윤활제 항진균성 겔 조성물 |
| US20040033968A1 (en) | 2002-08-16 | 2004-02-19 | Lin Shun Y. | Optimal volume of intra-vaginal semisolid dosage forms for treating vaginal infections |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
| JP2006505583A (ja) | 2002-10-25 | 2006-02-16 | フォーミックス エルティーディー． | 化粧剤および医薬用フォーム |
| US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| US20050186142A1 (en) | 2002-10-25 | 2005-08-25 | Foamix Ltd. | Kit and composition of imidazole with enhanced bioavailability |
| US20070292355A1 (en) | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Anti-infection augmentation foamable compositions and kit and uses thereof |
| DE10261656A1 (de) | 2002-12-23 | 2004-07-01 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
| US20050026982A1 (en) | 2003-06-10 | 2005-02-03 | Soenke Johannsen | Composition that consists of alkanedicarboxylic acids and a pharmaceutical active ingredient |
| JP2007508243A (ja) | 2003-08-04 | 2007-04-05 | フォーミックス エルティーディー． | 両親媒性コポリマーゲル化剤を含む泡坦体 |
| US20060140990A1 (en) * | 2003-09-19 | 2006-06-29 | Drugtech Corporation | Composition for topical treatment of mixed vaginal infections |
| CN1304002C (zh) * | 2003-12-02 | 2007-03-14 | 浙江巨都集团股份有限公司 | 塞克硝唑阴道泡腾片及其生产方法 |
| US20050222169A1 (en) | 2004-01-16 | 2005-10-06 | Nawaz Ahmad | Compositions and methods of treating infections |
| US8309103B2 (en) * | 2004-01-22 | 2012-11-13 | Alparis, S.A. De C.V. | Association of fluconazole-tinidazole for the treatment of vaginal infections, its composition, preparation process and usage |
| AU2005207037A1 (en) | 2004-01-22 | 2005-08-04 | Nitromed, Inc. | Nitrosated and/or nitrosylated compounds, compositions and methods of use |
| US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| US20060024243A1 (en) | 2004-08-02 | 2006-02-02 | Agis Industries (1983) Ltd. | Foamable compositions containing nitro-imidazoles, processes for preparing same and methods of treatment utilizing same |
| US7485729B2 (en) | 2004-08-12 | 2009-02-03 | King Industries, Inc. | Organometallic compositions and coating compositions |
| WO2006021303A1 (de) | 2004-08-24 | 2006-03-02 | Basf Aktiengesellschaft | Imidazolium-methylsulfite als ausgangsverbindungen zur herstellung ionischer flüssigkeiten |
| US20060137684A1 (en) | 2004-12-01 | 2006-06-29 | Celeste Evans | Compositions and methods of treating irritation and kit therefor |
| US20060142304A1 (en) | 2004-12-27 | 2006-06-29 | Michael Southall | Method for treating or preventing pruritic and neurogenic skin disorders |
| WO2006120495A1 (fr) | 2005-05-13 | 2006-11-16 | Advanced Scientific Developements | Composition pharmaceutique comprenant un antiviral, an antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol, le thymol, l’eugenol, le borneol et le carvacrol |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| CN1789250A (zh) | 2005-12-16 | 2006-06-21 | 西安新安医药科技有限公司 | 一组硝基咪唑类衍生物的光学对映体、制备方法及其用途 |
| US20070154510A1 (en) | 2005-12-30 | 2007-07-05 | Wilcher Steve A | Adsorbent-Containing Hemostatic Devices |
| EP1968544A2 (en) | 2006-01-05 | 2008-09-17 | Drugtech Corporation | Drug delivery system for bioadhesion to a vulvovaginal surface |
| US20100159035A1 (en) | 2006-04-04 | 2010-06-24 | Avner Shemer | Kit for treating skin infection |
| CN1973838A (zh) * | 2006-11-28 | 2007-06-06 | 湖北科益药业股份有限公司 | 塞克硝唑片及其制备方法 |
| US9398949B2 (en) | 2007-01-29 | 2016-07-26 | Emmetropia, Inc. | Intraocular lens system |
| US20110002866A1 (en) | 2007-10-31 | 2011-01-06 | Lubit Beverly W | Methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent |
| WO2009058387A2 (en) | 2007-11-02 | 2009-05-07 | Nektar Therapeutics Al, Corporation | Oligomer-nitroimidazole anti-infective conjugates |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| US7893097B2 (en) | 2008-02-02 | 2011-02-22 | Dow Pharmaceutical Sciences, Inc. | Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water |
| JP2011512354A (ja) | 2008-02-14 | 2011-04-21 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | 神経機能障害を検知するための新規の造影剤 |
| CN101255175A (zh) | 2008-03-28 | 2008-09-03 | 合肥工业大学 | 一种塞克硝唑水溶性盐及其制备方法 |
| US9493489B2 (en) | 2008-10-15 | 2016-11-15 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-protozoal agents |
| US20100304998A1 (en) | 2009-06-02 | 2010-12-02 | Marquette University | Chemical Proteomic Assay for Optimizing Drug Binding to Target Proteins |
| DE112010004110T8 (de) | 2009-10-22 | 2012-12-06 | Thomas Julius Borody | Neue parasitentherapie |
| EP2495563A4 (en) | 2009-10-26 | 2013-04-10 | Fujifilm Ri Pharma Co Ltd | DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES |
| EP2493471B1 (en) | 2009-10-26 | 2019-11-27 | Thomas Julius Borody | Novel enteric combination therapy |
| WO2012075015A2 (en) | 2010-11-29 | 2012-06-07 | Dr. Reddy's Laboratories Ltd. | Oral metronidazole pharmaceutical compositions |
| WO2012106264A2 (en) | 2011-01-31 | 2012-08-09 | The Trustees Of Columbia University In The City Of New York | Treatment and prevention of bacterial vaginosis and gardnerella vaginalis infections |
| ES2673286T3 (es) | 2011-02-11 | 2018-06-21 | Zx Pharma, Llc | Formulaciones multiparticuladas de L-mentol y métodos relacionados |
| US8912113B2 (en) | 2011-03-06 | 2014-12-16 | King Industries, Inc. | Compositions of a metal amidine complex and second compound, coating compositions comprising same |
| FR2975299B1 (fr) | 2011-05-16 | 2013-09-27 | Madeca | Utilisation du secnidazole dans le traitement des infections dentaires |
| HUE047170T2 (hu) | 2011-05-16 | 2020-04-28 | Starpharma Pty Ltd | Bakteriális vaginózis kezelési vagy megelõzési módszere |
| CN102266284A (zh) | 2011-06-20 | 2011-12-07 | 湖北东信药业有限公司 | 塞克硝唑阴道栓剂及其制备工艺 |
| CA2840571C (en) * | 2011-06-28 | 2020-03-24 | Medicis Pharmaceutical Corporation | High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis |
| CN102335433B (zh) | 2011-10-09 | 2013-01-02 | 广东华南药业集团有限公司 | 用于微丸压片的包衣膜及其制备方法 |
| HK1219022A1 (zh) | 2013-02-04 | 2017-03-24 | Seres Therapeutics, Inc. | 填充胃肠道的方法 |
| US20140271923A1 (en) * | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
| WO2016037131A1 (en) | 2014-09-05 | 2016-03-10 | Symbiomix Therapeutics, Llc | Secnidazole for use in the treatment of bacterial vaginosis |
| CN104257626A (zh) | 2014-10-14 | 2015-01-07 | 武汉科技大学 | 一种塞克硝唑软胶囊及其制备方法 |
| CA2988082C (en) | 2015-06-01 | 2020-09-29 | Symbiomix Therapeutics, Llc | Novel nitroimidazole formulations and uses thereof |
| US10596832B2 (en) | 2018-05-24 | 2020-03-24 | Xerox Corporation | Printer and dryer for drying images on coated substrates in aqueous ink printers |
-
2015
- 2015-09-04 WO PCT/US2015/048681 patent/WO2016037131A1/en not_active Ceased
- 2015-09-04 CA CA2959414A patent/CA2959414C/en active Active
- 2015-09-04 US US14/846,505 patent/US10335390B2/en active Active
- 2015-09-04 JP JP2017512757A patent/JP6487534B2/ja active Active
- 2015-09-04 AU AU2015311674A patent/AU2015311674B2/en active Active
- 2015-09-04 KR KR1020177009154A patent/KR20170052626A/ko not_active Ceased
- 2015-09-04 KR KR1020197006430A patent/KR20190026962A/ko not_active Ceased
-
2018
- 2018-06-01 AU AU2018203882A patent/AU2018203882B2/en active Active
- 2018-07-30 US US16/049,032 patent/US10682338B2/en active Active
- 2018-08-15 AU AU2018217262A patent/AU2018217262B1/en active Active
- 2018-12-06 JP JP2018228992A patent/JP2020019759A/ja active Pending
-
2019
- 2019-01-04 JP JP2019000253A patent/JP6637624B2/ja not_active Expired - Fee Related
- 2019-05-03 US US16/403,176 patent/US10849884B2/en active Active
- 2019-06-13 CA CA3046521A patent/CA3046521A1/en active Pending
- 2019-07-23 KR KR1020190088946A patent/KR20200013602A/ko not_active Withdrawn
- 2019-09-27 US US16/586,372 patent/US11020377B2/en active Active
- 2019-09-27 US US16/586,339 patent/US10857133B2/en active Active
-
2020
- 2020-03-12 US US16/817,246 patent/US11000507B2/en active Active
- 2020-06-02 US US16/890,526 patent/US11324721B2/en active Active
- 2020-06-15 US US16/901,739 patent/US11000508B2/en active Active
- 2020-06-29 KR KR1020200079140A patent/KR20200083958A/ko not_active Withdrawn
- 2020-12-03 JP JP2020201018A patent/JP2021042246A/ja active Pending
-
2021
- 2021-05-07 US US17/314,833 patent/US11602522B2/en active Active
- 2021-05-31 US US17/335,016 patent/US11684607B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20190026962A (ko) | 세균질증 치료에 사용하기 위한 세크니다졸 | |
| WO2011041938A1 (zh) | 一种以苯甲酸和有机酸防腐剂相联合作为有效成分的组合物及其用途 | |
| AU2019359210A1 (en) | Methods of making and using pH modulating compositions in the reproductive system | |
| RU2632110C2 (ru) | Способ лечения или профилактики бактериального вагиноза | |
| Karaosmanoglu et al. | Hyaluronic acid in the treatment of postmenopausal women with atrophic vaginitis | |
| Yantis et al. | Cimetidine-induced exfoliative dermatitis | |
| RU2821032C1 (ru) | Способы лечения заболеваний, связанных с рецептором s1p1 | |
| US12280037B2 (en) | Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof | |
| Chou et al. | Analysis of metabolic pathways as a novel clinical biomarkers of endometriosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20190304 Application number text: 1020177009154 Filing date: 20170404 |
|
| PG1501 | Laying open of application | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20200804 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200904 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20201116 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20210621 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20201116 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |